Bayer Continues Pursuit Of Aspirin Primary MI Prevention Labeling
This article was originally published in The Tan Sheet
Executive Summary
Bayer is seeking FDA's input on how it can expand professional labeling for aspirin to include a primary myocardial infarction prevention indication
You may also be interested in...
CHARISMA May Make Bayer Primary MI Prevention Petition More Popular
Bayer's bid for an indication for the primary prevention of MI on professional aspirin labeling may be strengthened by data from the CHARISMA trial
CHARISMA May Make Bayer Primary MI Prevention Petition More Popular
Bayer's bid for an indication for the primary prevention of MI on professional aspirin labeling may be strengthened by data from the CHARISMA trial
CHARISMA May Make Bayer Primary MI Prevention Petition More Popular
Bayer's bid for an indication for the primary prevention of MI on professional aspirin labeling may be strengthened by data from the CHARISMA trial